BioSpace News Archive

Orthofix and SeaSpine announced they have entered into a definitive agreement to combine in an all-stock merger of equals.

Biodesix, Inc. announced that the Company expects to report third quarter 2022 total revenue to be in the range of $10.6 million to $11.2 million, representing growth of 62% to 71% over the third quarter 2021.

1910 Genetics today announced that it has appointed Patrick Genestin as Chief Business Officer.

Eyam Vaccines and Immunotherapeutics ltd. today announced a partnership with Mitacs to fund Post-Doctoral Fellowships at the University of British Columbia (UBC).

Companies jointly submitted a $750,000 USD application to BARDA to use Prepaire™ Shield discovery platform to assess repurposed drugs combined with onternabez as Chemical Threat Medical Countermeasures.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022.

TFF Pharmaceuticals, Inc. today shared further details on the poster presentations featuring the Company’s Thin Film Freezing Technology at the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 Meeting, which is being held in Boston from October 16-19, 2022.

Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development.

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or the ‘Company’) is pleased to announce that it has completed a constructive pre-Investigational New Drug Application (‘pre-IND’) meeting with the U.S. Food and Drug Administration (‘FDA’) for its proprietary drug product IHL-216A for treatment of traumatic brain injury and concussion (‘TBI’).

Sirius Medical, the leader in surgical marker navigation, is proud to support the 41st European Society of Surgical Oncology Congress in Bordeaux, France.